Report interim data from the Phase 1 clinical trial

Deadline passed; outcome being checked

What the company said

“The company anticipates reporting interim data from this Phase 1 trial in the second half of 2021 through the second half of 2022.”

SourceOncorus, Inc. Form 8-K press release, 2021-01-04
FilingSEC filing index
Deadline as statedsecond half of 2022
Deadline used31 Dec 2022, the last day of the stated period
TypeProduct
Permanent referenceKI-C-2021-C671818-020978
Cite as https://keptindex.org/c/KI-C-2021-C671818-020978/ — this address never changes.

The deadline has passed. We check for public evidence starting 30 days after the deadline, and repeat the check if nothing clear turns up.

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Version 1 · original · stated 4 Jan 2021

Deadline 31 Dec 2022 (“second half of 2022”) · wording expected
Version 2 · stated 10 Mar 2021

Deadline 31 Dec 2021 (“in the second half of 2021”) · wording expected

“Oncorus anticipates reporting interim data from its ongoing Phase 1 clinical trial of its lead oHSV-based clinical candidate ONCR-177 ... in the second half of 2021”
Source for this version

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Commitment recordedThe company's words were matched word for word against the filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you Oncorus, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.